Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Prime Medicine, Inc.

Get SEC filing alerts via email and in your feed for Prime Medicine, Inc.

PRME

Prime Medicine, Inc.

About Prime Medicine, Inc.

Prime Medicine is a biotechnology company specializing in developing precise, one-time gene editing therapies using its proprietary Prime Editing technology. Focused on genetic diseases like chronic granulomatous disease and Wilson’s disease, it aims to correct mutations across various tissues and cell types. The company leverages innovative delivery platforms and strategic partnerships to create durable, potentially curative treatments with broad therapeutic applications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Prime Medicine, Inc.

1
1
Prime Medicine, Inc. Prime Medicine Reports Q1 2026 Financial Results with Decreased Revenue and Net Loss

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Prime Medicine, Inc. Prime Medicine Reports $201.1 Million Net Loss for 2025, Faces Funding Challenges

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Prime Medicine, Inc. Prime Medicine Reports $1.2M Revenue in Q3 2025, Net Loss of $50.6M

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Prime Medicine, Inc. Prime Medicine Reports $1.1 Million Revenue in Q2 2025, Continues to Operate at a Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Prime Medicine, Inc. Prime Medicine Reports $1.454 Million Revenue in Q1 2025, Net Loss Widens to $51.9 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Prime Medicine, Inc. Prime Medicine Reports $195.9 Million Net Loss for 2024, Highlights Strategic Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Prime Medicine, Inc. Prime Medicine Reports Strong Financials, Collaboration Revenue Growth, and Strategic Partnerships in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments